✦ LIBER ✦

505 Conversion of liver transplant recipients with hepatitis B virus from hepatitis B immune globulin (HBIG) and lamivudine (LAM) to adefovir dipivoxil (ADV) and LAM

✍ Scribed by G.W. Neff; V.C. Zacharias; M. Alonzo; N. Kenner; E. Weber; T.E. Kaiser; K. Safdar; E. Rideman; M. Thomas; J. Martin; S. Rudich; A. Tevar; J. Buell

Book ID: 117374782
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 134 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80505-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in alanine aminotransferase (ALT

Changes in alanine aminotransferase (ALT) and YMDD mutation profile associated with switching from lamivudine (LAM) to either adefovir dipivoxil (ADV) or combination LAM plus ADV in chronic hepatitis B (CHB) patients with LAM resistance

✍ Peters, Marion; Martin, Paul; Sullivan, Mark; Kleber, Kristin; Ebrahimi, Ramin; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 247 KB

Evolution of hepatitis B virus sequence

Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy

✍ Kyun-Hwan Kim; Kwang-Hee Lee; Hye-Young Chang; Sang Hoon Ahn; Shuping Tong; Youn 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

## Abstract Recurrent hepatitis B virus (HBV) infection after liver transplantation can be prevented by prophylactic hepatitis B immune globulin (HBIG) and lamivudine therapy. However, reinfection may still occur due to the emergence of immune escape mutants and mutants of the YMDD motif. The full

7 Adefovir dipivoxil (ADV) provides sign

7 Adefovir dipivoxil (ADV) provides significant clinical benefit, reduces meld score and prevents transplantation in chronic hepatitis B patients wait-listed for liver transplantation (OLT) with lamivudine-resistance (LAM-R)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 117 KB

A randomized study comparing lamivudine

A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation

✍ Marı́a Buti; Antoni Mas; Martı́n Prieto; Fernando Casafont; Antonio González; Ma 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 115 KB

438 Continued safety and efficacy of add

438 Continued safety and efficacy of adding adefovir dipivoxil (ADV) to ongoing lamivudine (LAM) therapy in compensated chronic hepatitis B (CHB) patients with YMDD variant HBV: 2 year results

✍ R. Perrillo; B. Willems; N. Leung; C. Trepo; H.W.L. Hann; G. Lau; W.M. Lee; E. S 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Conversion from intravenous to intramusc

Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation

✍ Steven-Huy Han; Paul Martin; Marc Edelstein; Rena Hu; Gregg Kunder; Curtis Holt; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB